Schonfeld Strategic Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.2K	Buy	26,589 +4,853	+22%	+$2.95K	﹤0.01%	2070
2025 Q4	$14.4K	Buy	21,736 +10,853	+100%	+$39.2K	﹤0.01%	1945
2025 Q3	$38.6K	Buy	+10,883	New	+$32.5K	﹤0.01%	2077
2023 Q4	–	Sell	-138,500	Closed	-$726K	–	2258
2023 Q3	$726K	Buy	+138,500	New	+$615K	0.01%	1113
2022 Q3	–	Sell	-5,837	Closed	-$155K	–	3185
2022 Q2	$155K	Buy	5,837 +7	+0.1%	+$247	﹤0.01%	1991
2022 Q1	$217K	Sell	5,830 -7,043	-55%	-$307K	﹤0.01%	1901
2021 Q4	$753K	Sell	12,873 -1,210	-9%	-$78.7K	0.01%	1068
2021 Q3	$1.16M	Sell	14,083 -6,370	-31%	-$554K	0.01%	905
2021 Q2	$1.93M	Buy	20,453 +11,460	+127%	+$849K	0.02%	720
2021 Q1	$574K	Buy	8,993 +6,390	+245%	+$427K	0.01%	1095
2020 Q4	$152K	Buy	+2,603	New	+$66.4K	﹤0.01%	1393

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schonfeld Strategic Advisors's VTGN Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its VistaGen Therapeutics (VTGN) stake by 22% in Q1 2026, buying an estimated $2.95K and bringing the position to 26,589 shares worth $15.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

Schonfeld Strategic Advisors first reported a position in VTGN in Q4 2020 and has held it in 11 quarters since. The position peaked at $1.93M in Q2 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

Schonfeld Strategic Advisors held 26,589 shares of VistaGen Therapeutics worth $15.2K as of Q1 2026.
Schonfeld Strategic Advisors bought 4,853 VistaGen Therapeutics shares in Q1 2026, an estimated $2.95K.
VistaGen Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #2070 holding.
Schonfeld Strategic Advisors first reported a position in VistaGen Therapeutics in Q4 2020 and has held it in 11 quarters since.
Schonfeld Strategic Advisors's VistaGen Therapeutics position peaked at $1.93M in Q2 2021.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.